Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
The Journal of Experimental Medicine|September 9, 1998
Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosisY Gao, J M Herndon, H Zhang, et al.Cancer Gene Therapy|September 15, 2007
DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cellsA D Sanlioglu, B Karacay, I T Koksal, et al.Science (New York, N.Y.)|November 17, 1995
Fas ligand-induced apoptosis as a mechanism of immune privilegeT S Griffith, T Brunner, S M Fletcher, et al.Immunity|July 1, 1996
CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological toleranceT S Griffith, X Yu, J M Herndon, et al.Behring Institute Mitteilungen|October 1, 1996
Regulation of CD95 ligand expression: a key element in immune regulation?T Brunner, N J Yoo, T S Griffith, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 18, 2000
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosisT S Griffith, R D Anderson, B L Davidson, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1998
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cellsT S Griffith, W A Chin, G C Jackson, et al.The Journal of Clinical Investigation|February 1, 1997
CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survivalP M Stuart, T S Griffith, N Usui, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2001
Regulation of Fas ligand-induced apoptosis by TNFB D Elzey, T S Griffith, J M Herndon, et al.The Journal of Experimental Medicine|April 20, 1999
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAILT S Griffith, S R Wiley, M Z Kubin, et al.Pageof 3